Logo

Astellas and Seattle Genetics Report Results of Enfortumab Vedotin in P-II EV-201 Study for Patients with Locally Advanced or Metastatic Urothelial Cancer #ASCO2019

Share this

Astellas and Seattle Genetics Report Results of Enfortumab Vedotin in P-II EV-201 Study for Patients with Locally Advanced or Metastatic Urothelial Cancer #ASCO2019

Shots:

  • The P-II EV-201 study involves assessing of Enfortumab Vedotin in patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor including those who have also been treated with Pt-CT
  • P-II EV-201 results: ORR 44%; DOR 7.6 mos.; mOS 11.7 mos.; mPFS 5.8 mos.; CR 12%; presented at ASCO 2019
  • Enfortumab vedotin is an investigational ADC candidate targeting Nectin-4 protein- currently evaluated in P-III EV-301 study for LA or metastatic urothelial cancer. In 2007- Seattle and Astellas entered a co-development deal for enfortumab vedotin- plans to submit BLA to FDA based on EV-201 results

Click here to read full press release/ article

 Ref: Astellas| Image:Astellas


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions